For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Helixmith Co., Ltd

USPTO Granted Patents = 13

EPO Patents = 4

Trademarks = 2

Forward Citations = 2

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Jae-Gyun Jeong (4 out of 5 patents)

Seung Shin Yu (3 out of 6 patents)

Jae Gyun Jeong (3 out of 4 patents)

4. Doo Suk Lee (3 out of 4 patents)

5. Nayeon Lee (2 out of 2 patents)

6. Mi Won Son (2 out of 6 patents)

7. JungHun Lee (2 out of 21 patents)

8. Min Jung Bae (2 out of 2 patents)

9. Won Woo Lee (2 out of 4 patents)

10. Jung Hun Lee (2 out of 96 patents)

11. Kevin Friedman (1 out of 21 patents)

12. Jin-A Chae (1 out of 4 patents)

13. Dongsik Kim (1 out of 1 patent)

14. Juwon Shim (1 out of 1 patent)

15. Byeong Seon Chang (1 out of 15 patents)

13 patents: Sort by Forward Citations

1. 12180287 - Anti-c-Met antibody showing enhanced stability or antigen-binding fragments thereof (2024-12-31),

2. 11975039 - Herbal composition for treatment of attention deficit hyperactivity disorder (2024-05-07),

3. 11634728 - Adeno-associated virus (AAV) vector having hybrid HGF gene introduced thereto (2023-04-25),

4. 11559555 - Crude drug composition for preventing or treating respiratory diseases (2023-01-24),

5. 11554179 - Lyophilized pharmaceutical compositions for naked DNA gene therapy (2023-01-17),

6. 11541097 - Crude drug composition for preventing or treating respiratory diseases (2023-01-03),

7. 11510999 - Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms (2022-11-29),

8. 11279769 - Anti-Sialyl Tn chimeric antigen receptors (2022-03-22),

9. 11219667 - Method for treating peripheral vascular disease using hepatocyte growth factor and stromal cell derived factor 1A (2022-01-11),

10. 10927177 - Methods of treatment using anti-c-met antibodies (2021-02-23),

11. RE48404 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor (2021-01-25),

12. 10759841 - Gene therapy for diabetic neuropathy using an HGF isoform (2020-09-01),

13. 10639351 - Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor (2020-05-05),

Company Overview

Helixmith Co., Ltd, based in Seoul, South Korea, specializes in the development of innovative biopharmaceutical products. The company focuses on gene therapy and regenerative medicine, leveraging advanced technologies to create treatments for various diseases. With a commitment to improving patient outcomes, Helixmith is engaged in research that aims to address unmet medical needs through cutting-edge therapeutic solutions. Its expertise in biotechnology positions it as a key player in the evolving landscape of healthcare innovation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

13 Patents

#318 in Seoul

#876 in South Korea

#45,039 in the World

Seoul, South Korea

Helixmith Co., Ltd

Forward Citations = 2

26 inventors:

Jae-Gyun Jeong (4 out of 5 patents)

Seung Shin Yu (3 out of 6 patents)

Jae Gyun Jeong (3 out of 4 patents)

4. Doo Suk Lee (3 out of 4 patents)

5. Nayeon Lee (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Helixmith Co., Ltd. Retrieved from https://idiyas.com/company/helixmith-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…